Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Centrexion Therapeutics Corporation

Boehringer Ingelheim Pharma Kg

Stephan Georg Mueller

Klaus Rudolf

Dirk Stenkamp

Henri Doods

Philipp Lustenberger

Gerhard Schaenzle

Kirsten Arndt

Marco Santagostino

Alexander Dreyer

Fabio Paleari

Marcus Schindler

Gerald Juergen Roth

Thorsten Lehmann-Lintz

Annekatrin Charlotte Heimann

Dirk Gottschling

Georg Dahmann

Doris Riether

Florian Paul Christian Binder

Achim Sauer

Janet Rachel Nicholson

Eckhart Bauer

Leo Thomas

Ralf Lotz

Ralf R H Lotz

Kai Gerlach

Rudolf Hurnaus

Martin Lenter

Armin Heckel

Wolfgang Eberlein

Henning Priepke

Joerg Kley

Thierry Bouyssou

Alexander Pautsch

Thomas Trieselmann

Marc Grundl

Klaus Klinder

Bernd Wellenzohn

Bradford S Hamilton

Heike-Andrea Wieland

Ursula Mueller-Vieira

Kristen Arndt

Philip Lustenberger

Henri Doobs

Kelly Allers

Florian Binder

Rudlof Klaus

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

The present invention relates to novel 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamides of formula A and pharmaceutically acceptable salts thereof, wherein Rto Rare as defined herein. The invention also relates to processes for the preparation of these compound, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions in which inhibition of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme may be beneficial.

2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazolesand-[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R, Rand Rare defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

Pyrimidine derivatives which are CGRP&#x2014;antagonists

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R, R, R, R, Q have meanings given in the description.

Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors

Disclosed are (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R, R, Rand Rare defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

Compounds

The present invention relates to new CGRP-antagonists of general formula I wherein R, R, R, R, R, R, X, Y and Z are defined as mentioned hereinafter, the individual diastereomers, the individual enantiomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

Substituted piperazines as CGRP antagonists

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R, Rand Rare defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

CGRP antagonists

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, Rand Rhave the meanings given in claim. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to novel CGRP antagonists of the general formula (I) in which U, V, X, Y, R, R, Rare defined as described below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, and the hydrates of the salts, particularly the physiologically compatible salts thereof having inorganic or organic acids or bases, pharmaceuticals comprising said compounds, the use thereof, and the method for the production thereof. 

The present invention relates to new CGRP-antagonists of general formulae Ia and Ib wherein R, R, R, Rand Rare defined as mentioned below, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Growing community of inventors

Warthausen, Germany

Stephan Georg Mueller